Hledání v detailu akcií
Top akcie
NázevNávštěvy
19 188
879
854
807
610
539
528
384
378
374
Moje portfolio
Nastavit Oblíbené, nastavit Portfolio
Oblíbené tituly
select
NázevNejlepší
nákup
Nejlepší
prodej
Změna
(%)
ČEZ-0,09
KB-0,49
PKN82,72830,85
Msft-0,72
Nokia5,0585,064-0,98
IBM-0,97
DCX57,8557,86-4,32
PFE-0,44
22.6.2018 1:39:00
Indexy online
AD Index online
select
AD Index online
 

  • 21.6.2018 22:00:00
GlycoMimetics (NASDAQ Cons)
Poslední obchod Změna (%) Změna (USD) Objem obchodů (ks)
14,89 -5,88 -0,93 469 270
R - Real-Time data si mohou aktivovat klienti Patria Plus / Investor Plus ZDE.

 
  • Poslední aktualizace: 22.6.2018
Popis společnosti
Obecné informace
Název společnostiGlycoMimetics Inc
TickerGLYC
Kmenové akcie:Ordinary Shares
RICGLYC.O
ISINUS38000Q1022
Poslední známé roční výsledky31.12.2017
Poslední známé čtvrtletní výsledky31.3.2018
Počet zaměstnanců k 31.12.2017 40
Akcie v oběhu k 18.5.2018 42 491 487
Počet akcionářů k 31.12.2017 32
MěnaUSD
Kontaktní informace
Ulice9708 Medical Center Dr
MěstoROCKVILLE
PSČ20850-3343
ZeměUnited States
Kontatní osoba 
Funkce kontaktní osoby 
Telefon12 402 431 201
Fax12402431018

Business Summary: GlycoMimetics, Inc. is a clinical-stage biotechnology company. The Company focuses on the discovery and development of glycomimetic drugs. The Company operates through the identification and development of glycomimetic compounds segment. The Company is developing its lead drug candidate, GMI-1070 (Rivipansel), for the treatment of vaso-occlusive crisis (VOC), a debilitating and painful condition that occurs periodically throughout the life of a person with sickle cell disease. The Company is developing GMI-1271, a specific E-selectin inhibitor, to be used in combination with chemotherapy to treat patients with acute myeloid leukemia (AML), multiple myeloma (MM) and other hematologic cancers. The Company has an additional drug candidate, GMI-1359, that targets both E-selectin and a chemokine receptor, CXCR4. The Company is also advancing other preclinical-stage programs, which include small-molecule glycomimetic compounds that inhibit the proteins galectin-3 and galectin-9.
Financial Summary: BRIEF: For the three months ended 31 March 2018, GlycoMimetics Inc revenues was not reported. Net loss increased 45% to $11.5M. Higher net loss reflects researcg and development expense balanc increase of 54% to $8.6M (expense), General & Administrative Expe increase of 39% to $2.2M (expense), General and administrative expense increase of 30% to $691K (expense).
Odvětvová klasifikace
TRBC2009Biotechnology / Medical Research
TRBC2012Bio Therapeutic Drugs
RBSS2004Biotechnology
MGINDUSTRYBiotechnology & Drugs
MGSECTORHealthcare
NAICSResearch and Development in the Physical, Engineering, and Life Sciences
NAICSPharmaceutical Preparation Manufacturing
SICPharmaceutical Preparations
SICCommercial Physical Research
SICPharmaceutical Preparations



  • Poslední aktualizace: 22.6.2018
Management společnosti
FunkceJménoVěkVe funkci odVe firmě od
Independent Chairman of the BoardM. James Barrett74
President, Chief Executive Officer, Co-Founder, DirectorRachel King571.1.2003
Co-Founder, Senior Vice President, Chief Scientific Officer, DirectorJohn Magnani641.1.2003
Chief Financial OfficerBrian Hahn42
Senior Vice President - Clinical Development, Chief Medical OfficerHelen Thackray47